Monoclonal Antibodies Market in Colorectal Cancer to 2019
GBI Research, has released the pharma report - “Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient’s lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin, which generated revenues of $6.2 billion in 2012 across a number of oncology indications.
View full press release